Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Shinnosuke Kawahara

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5113191084. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2022: 1 paper · 2023: 3 papers · 2024: 5 papers · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  2. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  3. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Co-author DOI 10.1007/s00423-024-03512-8↗
  4. Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… Co-author DOI 10.1186/s12885-024-13244-z↗
  5. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  6. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16970↗
  7. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Co-author DOI 10.21873/anticanres.17286↗
  8. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. First author DOI 10.1186/s12957-023-03141-3↗
  9. Carbon Ion Radiotherapy Versus Perioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16222↗
  10. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. First author DOI 10.21873/anticanres.16327↗
  11. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-022-02481-0↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masaaki Murakawa · 11 shared papers, 2022–2026 · strength 1.95
  2. Makoto Ueno · 11 shared papers, 2022–2026 · strength 1.95
  3. Soichiro Morinaga · 11 shared papers, 2022–2026 · strength 1.95
  4. Naoto Yamamoto · 10 shared papers, 2022–2025 · strength 1.71
  5. Yuto Kamioka · 9 shared papers, 2022–2026 · strength 1.59
  6. Satoshi Kobayashi · 5 shared papers, 2023–2026 · strength 0.93
  7. Mariko Kamiya · 5 shared papers, 2023–2026 · strength 0.92
  8. Toru Aoyama · 4 shared papers, 2023–2024 · strength 0.69
  9. Toru Aoyama · 3 shared papers, 2024–2025 · strength 0.54
  10. Takashi Oshima · 3 shared papers, 2023–2024 · strength 0.52
  11. Hiroshi Tamagawa · 3 shared papers, 2022–2024 · strength 0.46
  12. Kota Washimi · 2 shared papers, 2025–2026 · strength 0.44
  13. Yohei Miyagi · 2 shared papers, 2025–2026 · strength 0.44
  14. Manabu Morimoto · 2 shared papers, 2022–2023 · strength 0.29
  15. Shiro Koizume · 1 shared paper, 2026 · strength 0.24
  16. Yukihiko Hiroshima · 1 shared paper, 2025 · strength 0.20
  17. Robert M. Hoffman · 1 shared paper, 2025 · strength 0.20
  18. Hiroyuki Katoh · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.